Lead. A narrative review published this month in CNS & Neurological Disorders Drug Targets examines the neuropsychiatric risks of zolpidem, one of the most widely prescribed hypnotics worldwide, and weighs them against emerging alternatives such as orexin receptor antagonists and melatonin-based therapies. The authors, a team from Desh Bhagat University in Punjab, India, argue that the growing medicolegal and clinical case record around zolpidem-associated behavioral toxicity demands a more individualized, ethically informed approach to prescribing.
The zolpidem problem. Zolpidem, a non-benzodiazepine sedative-hypnotic acting on GABA-A receptors, has long been valued for its rapid onset and relatively short half-life. But the review, based on PubMed/MEDLINE, Scopus, and Web of Science literature from 2020 to 2025, documents a consistent pattern of neuropsychiatric adverse events that complicate its real-world use.
The most striking category involves complex sleep behaviors. Patients under zolpidem have been documented sleep-driving, sleep-eating, making phone calls, and even attempting to operate machinery while in an apparent dissociated state with no subsequent recollection. The review notes these events occur most frequently at higher doses and in patients with preexisting psychiatric comorbidities. Cases of anterograde amnesia, hallucinations, and paradoxical disinhibition are also well represented in the literature.
Several case reports cited in the review involve criminal charges arising from behavior that occurred during zolpidem-induced altered consciousness. These cases raise difficult questions about intent, culpability, and the extent to which a prescribed medication can compromise a patient’s agency. A woman who caused a fatal traffic accident while sleep-driving under zolpidem, for example, faced legal proceedings that centered on whether she could be held criminally responsible for actions performed in a pharmacologically induced automatic state.
Populations at higher risk. The review identifies specific groups that appear particularly vulnerable to zolpidem’s adverse neuropsychiatric effects. Women metabolize zolpidem more slowly than men due to lower levels of CYP3A4 activity, leading to higher blood concentrations at equivalent doses. The U.S. Food and Drug Administration acknowledged this difference in 2013 when it lowered the recommended starting dose for women. Elderly patients face increased susceptibility due to age-related changes in drug clearance and greater sensitivity to sedative effects. Patients with psychiatric disorders, especially those already taking antidepressants or antipsychotics, face elevated risk of hallucinations, agitation, and complex behaviors. And patients on polypharmacy regimens face unpredictable drug-drug interactions that can potentiate zolpidem’s adverse effects.
The emerging alternatives. Against this backdrop, the review examines two classes of newer hypnotics that have entered clinical use or expanded their indications in recent years.
Orexin receptor antagonists, which promote sleep by blocking wake-promoting neuropeptide signaling rather than by broadly depressing central nervous system activity, show a more favorable adverse effect profile. They are associated with lower rates of complex sleep behaviors and less evidence of dependence or tolerance. Clinical trial data suggest they reduce sleep-onset latency and improve sleep maintenance with fewer next-day cognitive effects than zolpidem. However, the review notes that long-term safety data are still accumulating, and the drugs remain significantly more expensive than generic zolpidem.
Melatonin-based therapies, including prolonged-release melatonin and newer melatonin receptor agonists, offer what the authors describe as positive safety profiles. They do not appear to produce the kinds of complex behaviors or amnestic effects associated with zolpidem. Their principal limitation is comparatively lesser hypnotic efficacy. For patients with mild insomnia or circadian rhythm disturbances, melatonin-based options may be sufficient. For those with severe sleep-onset or sleep-maintenance difficulties, their clinical effect may fall short.
Implications for clinical practice. The central argument of the review is that the choice of hypnotic should not be driven by efficacy alone but by a careful, individualized weighing of risk. The authors recommend that zolpidem, where prescribed, be started at the lowest effective dose, with explicit warnings to patients about the possibility of complex sleep behaviors. They advise against combining zolpidem with alcohol, other CNS depressants, or high-dose psychiatric medications without close monitoring.
For patients in identified high-risk groups, the review suggests that orexin receptor antagonists or melatonin-based therapies may represent safer first-line choices, even if their hypnotic effect is less robust. Cost and access remain barriers to this approach in many healthcare systems, but the medicolegal and clinical costs of a single zolpidem-induced adverse event can dwarf the price difference.
The ethical dimensions are not limited to individual prescribing decisions. The authors point out that the pharmaceutical industry’s historical emphasis on zolpidem’s efficacy in registration trials, combined with relatively short follow-up periods, may have understated the prevalence of its most serious behavioral side effects. Broader pharmacovigilance systems, including spontaneous reporting databases and post-marketing surveillance, have been essential in surfacing the risks that pre-approval trials missed.
Source. Shafi T, Singh Z, Gulati P, Malik SH, Islam MM. Zolpidem and emerging hypnotics: neuropsychiatric adverse effects and ethical considerations for clinical practice. CNS Neurol Disord Drug Targets. 2026 Jul 16. doi: 10.2174/0118715273442470260706171716. PMID: 42473229.